Norbert Kraut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Norbert Kraut has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Gerlach
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
104 shared publications - Dorothea Rudolph
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
69 shared publications - Jörg Rinnenthal
Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria
60 shared publications - Darryl Benjamin McConnell
Boehringer Ingelheim RCV, Vienna, Austria
58 shared publications - Gerd Bader
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
42 shared publications - Ulrike Weyer-Czernilofsky
Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria
42 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Therapeutic Targeting of β-Catenin in Cancer
Mutations in CTNNB1 (encoding β-catenin), together with recurrent genetic alterations affecting the WNT signaling pathway, define one of the most prevalent oncogenic axes, collectively occurring in approximately 10% of human cancers. Thus, β-catenin is a prime target for precision oncology. Over the three decades following the pathway’s discovery, substantial progress has been made in elucidating how aberrant WNT/β-catenin signaling can drive cancer initiation, progression, and maintenance. Attempts to therapeutically address this pathway have, until recently, been unsuccessful. Approaches to block the pathway upstream of relevant mutations were ineffective, whereas progress in directly targeting β-catenin, either by blocking its interaction with key complex partners, most notably T-cell factor proteins, or by inducing β-catenin degradation, has long remained an unreachable goal for conventional drug discovery approaches. In this review, we describe opportunities and challenges in the development of therapies that directly aim to target β-catenin. We highlight recent progress based on novel approaches, suggesting that cracking this previously considered “undruggable” central oncogenic driver is becoming a reality. Effective targeting of β-catenin has the potential to address extensive unmet patient needs in hard-to-treat cancer types such as colorectal cancer, hepatocellular carcinoma, and other cancers driven by WNT/β-catenin pathway alterations.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Therapeutic Targeting of β-Catenin in Cancer
Mutations in CTNNB1 (encoding β-catenin), together with recurrent genetic alterations affecting the WNT signaling pathway, define one of the most prevalent oncogenic axes, collectively occurring in approximately 10% of human cancers. Thus, β-catenin is a prime target for precision oncology. Over the three decades following the pathway’s discovery, substantial progress has been made in elucidating how aberrant WNT/β-catenin signaling can drive cancer initiation, progression, and maintenance. Attempts to therapeutically address this pathway have, until recently, been unsuccessful. Approaches to block the pathway upstream of relevant mutations were ineffective, whereas progress in directly targeting β-catenin, either by blocking its interaction with key complex partners, most notably T-cell factor proteins, or by inducing β-catenin degradation, has long remained an unreachable goal for conventional drug discovery approaches. In this review, we describe opportunities and challenges in the development of therapies that directly aim to target β-catenin. We highlight recent progress based on novel approaches, suggesting that cracking this previously considered “undruggable” central oncogenic driver is becoming a reality. Effective targeting of β-catenin has the potential to address extensive unmet patient needs in hard-to-treat cancer types such as colorectal cancer, hepatocellular carcinoma, and other cancers driven by WNT/β-catenin pathway alterations.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Therapeutic Targeting of β-Catenin in Cancer
Current status of Wnt/β-catenin targeting agents.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Therapeutic Targeting of β-Catenin in Cancer
Current status of Wnt/β-catenin targeting agents.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (11) , 1819-1827
Therapeutic Targeting of β-Catenin in Cancer
Mutations in CTNNB1 (encoding β-catenin), together with recurrent genetic alterations affecting the WNT signaling pathway, define one of the most prevalent oncogenic axes, collectively occurring in approximately 10% of human cancers. Thus, β-catenin is a prime target for precision oncology. Over the three decades following the pathway’s discovery, substantial progress has been made in elucidating how aberrant WNT/β-catenin signaling can drive cancer initiation, progression, and maintenance. Attempts to therapeutically address this pathway have, until recently, been unsuccessful. Approaches to block the pathway upstream of relevant mutations were ineffective, whereas progress in directly targeting β-catenin, either by blocking its interaction with key complex partners, most notably T-cell factor proteins, or by inducing β-catenin degradation, has long remained an unreachable goal for conventional drug discovery approaches. In this review, we describe opportunities and challenges in the development of therapies that directly aim to target β-catenin. We highlight recent progress based on novel approaches, suggesting that cracking this previously considered “undruggable” central oncogenic driver is becoming a reality. Effective targeting of β-catenin has the potential to address extensive unmet patient needs in hard-to-treat cancer types such as colorectal cancer, hepatocellular carcinoma, and other cancers driven by WNT/β-catenin pathway alterations.
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (11) , 1819-1827
Open AccessTherapeutic Targeting of β-Catenin in Cancer
Mutations in CTNNB1 (encoding β-catenin), together with recurrent genetic alterations affecting the WNT signaling pathway, define one of the most prevalent oncogenic axes, collectively occurring in approximately 10% of human cancers. Thus, β-catenin is a prime target for precision oncology. Over the three decades following the pathway’s discovery, substantial progress has been made in elucidating how aberrant WNT/β-catenin signaling can drive cancer initiation, progression, and maintenance. Attempts to therapeutically address this pathway have, until recently, been unsuccessful. Approaches to block the pathway upstream of relevant mutations were ineffective, whereas progress in directly targeting β-catenin, either by blocking its interaction with key complex partners, most notably T-cell factor proteins, or by inducing β-catenin degradation, has long remained an unreachable goal for conventional drug discovery approaches. In this review, we describe opportunities and challenges in the development of therapies that directly aim to target β-catenin. We highlight recent progress based on novel approaches, suggesting that cracking this previously considered “undruggable” central oncogenic driver is becoming a reality. Effective targeting of β-catenin has the potential to address extensive unmet patient needs in hard-to-treat cancer types such as colorectal cancer, hepatocellular carcinoma, and other cancers driven by WNT/β-catenin pathway alterations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 3. Relationship between KRAS wild-type amplification and KRAS oncogenic activity in cell lines. RAS activation signatures (1,3) MSigDB, KrasLA, KRASG13D134, HRAS, MPAS, ras84 and RAS addiction in KRAS wild-type amplified cell lines (relative copy number >7) compared to cell lines with a lower relative copy number (2-7) and KRAS mutated cell lines without KRAS amplification. Enrichment scores were estimated using single sample enrichment (ssGSEA). A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7. Adjusted P-values (Benjamini-Hochberg) are displayed.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 3. Relationship between KRAS wild-type amplification and KRAS oncogenic activity in cell lines. RAS activation signatures (1,3) MSigDB, KrasLA, KRASG13D134, HRAS, MPAS, ras84 and RAS addiction in KRAS wild-type amplified cell lines (relative copy number >7) compared to cell lines with a lower relative copy number (2-7) and KRAS mutated cell lines without KRAS amplification. Enrichment scores were estimated using single sample enrichment (ssGSEA). A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7. Adjusted P-values (Benjamini-Hochberg) are displayed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.